Use of bilastine in clinical practice ? case reports Case reports
Article Sidebar
Main Article Content
Abstract
Allergic diseases are one of the largest groups of civilization disorders in the world. The main disease entities are allergic rhinitis and urticaria. Effective therapy for these conditions is based on second-generation antihistamines that selectively inhibit the H1 receptor. One of the most modern products of this group is bilastine, which is characterized by high efficacy and a very high safety profile. The publication presents cases from everyday clinical practice in which bilastine was used in patients with allergic rhinitis and urticaria.
Downloads
Article Details
Copyright: ? Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Shaker M. New insights into the allergic march. Curr Opin Pediatr. 2014; 26(4): 516-20.
3. GBD 2021 Asthma and Allergic Diseases Collaborators. Global, regional, and national burden of asthma and atopic dermatitis, 1990-2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Respir Med. 2025; 13(5): 425-46.
4. Samoliński B, Sybilski AJ, Raciborski F et al. Prevalence of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol Pol. 2009; 63(4): 324-30.
5. Dierick BJH, van der Molen T, Flokstra-de Blok BMJ et al. Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy. Expert Rev Pharmacoecon Outcomes Res. 2020; 20(5): 437-53.
6. Church MK, Maurer M, Simons FE. Global Allergy and Asthma European Network. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010; 65(4): 459-66.
7. Bousquet J, Schünemann HJ, Togias A et al. Allergic Rhinitis and Its Impact on Asthma Working Group. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020; 145(1): 70-80.
8. Bousquet J, Ansótegui I, Canonica GW et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin. 2012; 28(1): 131-9.
9. Bioequivalence and Safety of Bilastine 20 mg Orodispersible Tablets and Conventional Tablets: A Randomized, Single-Dose, Two-Period Crossover Study in Healthy Volunteers Under Fasting Conditions. Drugs RD. 2024; 24(3): 405-14.